Current status of bevacizumab in advanced ovarian cancer - PubMed (original) (raw)

Current status of bevacizumab in advanced ovarian cancer

Federica Tomao et al. Onco Targets Ther. 2013.

Abstract

Ovarian cancer is the most lethal gynecological cancer, mainly because of the delay in diagnosis. Recently, much effort has been put into investigating and introducing novel targeted agents into clinical practice, with the aim of improving prognosis and quality of life. Angiogenesis is a possible target. The aim of this review is to investigate the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in patients with ovarian cancer. These therapeutic strategies include monoclonal antibodies and tyrosine-kinase inhibitors. These drugs have as molecular targets vascular endothelial growth factor, vascular endothelial growth factor receptors, platelet-derived growth factor, fibroblast growth factor, and angiopoietin. Bevacizumab was investigated in several Phase III studies, with interesting results. Today, there is strong evidence for introducing bevacizumab in the treatment of patients with advanced and recurrent ovarian cancer. Nevertheless, further investigations and large clinical trials are needed to understand the safety and effectiveness of bevacizumab, the optimal duration and timing of treatment, and activity in association with other chemotherapeutic and targeted agents. It also is necessary to identify biologic factors predictive of efficacy to choose the most appropriate antiangiogenic agent in the integrated treatment of epithelial ovarian cancer.

Keywords: angiogenesis; bevacizumab; chemotherapy; epithelial ovarian cancer; vascular endothelial growth factor.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Evolution of medical therapy in ovarian cancer with new drugs under investigation. Abbreviations: EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; MEK, mitogen-activated protein kinase kinase; PIGFab, phosphatidylinositol-glycan biosynthesis class F; FTI, farnesyl transferase inhibitor; CHT, chemotherapy; TLK286, glutathione S-transferase P1-1 activated glutathione analogue; ACA125, murine anti-idiotypic antibody of the tumor-associated antigen CA-125; TAK165, 1−(4−{4−[(2−{(E)−2−[4−(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole; SCH6636, farnesyl protein transferase inhibitor; BMS214662, farnesyltransferase inhibitor.

Similar articles

Cited by

References

    1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–236. - PubMed
    1. Fleming GF, Ronnet BM, Seidman J, Zaino RJ, Rubin SC. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, editors. Principles and Practice of Gynecologic Oncology. 5th ed. Philadelphia: Lippincot Williams and Wilkins; 2009. pp. 763–836.
    1. Kusumbe AP, Bapat SA. Ovarian stem cell biology and the emergence of ovarian cancer stem cells. In: Bapat S, editor. Cancer Stem Cells: Identification and Targets. New York: John Wiley and Sons; 2008. pp. 95–110.
    1. Ozols RF. Update on the management of ovarian cancer. Cancer J. 2002;8(Suppl 1):S22–S30. - PubMed
    1. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991;9(10):1801–1805. - PubMed

LinkOut - more resources